Immune checkpoint inhibitors in mesothelioma: a turning point

被引：14

作者：

Ceresoli, Giovanni Luca ^{[1
]}

Pasello, Giulia ^{[2
,3
]}

机构：

[1] Clin Humanitas Gavazzeni, Dept Med Oncol, Thorac & GU Oncol Unit, I-24125 Bergamo, Italy

[2] Univ Padua, Dept Surg Oncol & Gastroenterol, Padua, Italy

[3] Ist Oncol Veneto IRCCS, Med Oncol 2, Padua, Italy

来源：

LANCET | 2021年 / 397卷 / 10272期

关键词：

MALIGNANT PLEURAL MESOTHELIOMA; TRIAL;

D O I：

10.1016/S0140-6736(21)00147-1

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：348 / 349

页数：2

共 12 条

[1] First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial [J].

Baas, Paul ;

Scherpereel, Arnaud ;

Nowak, Anna K. ;

Fujimoto, Nobukazu ;

Peters, Solange ;

Tsao, Anne S. ;

Mansfield, Aaron S. ;

Popat, Sanjay ;

Jahan, Thierry ;

Antonia, Scott ;

Oulkhouir, Youssef ;

Bautista, Yolanda ;

Cornelissen, Robin ;

Greillier, Laurent ;

Grossi, Francesco ;

Kowalski, Dariusz ;

Rodriguez-Cid, Jeronimo ;

Aanur, Praveen ;

Oukessou, Abderrahim ;

Baudelet, Christine ;

Zalcman, Gerard .

LANCET, 2021, 397 (10272) :375-386

[2] Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations [J].

Bueno, Raphael ;

Stawiski, Eric W. ;

Goldstein, Leonard D. ;

Durinck, Steffen ;

De Rienzo, Assunta ;

Modrusan, Zora ;

Gnad, Florian ;

Nguyen, Thong T. ;

Jaiswal, Bijay S. ;

Chirieac, Lucian R. ;

Sciaranghella, Daniele ;

Dao, Nhien ;

Gustafson, Corinne E. ;

Munir, Kiara J. ;

Hackney, Jason A. ;

Chaudhuri, Amitabha ;

Gupta, Ravi ;

Guillory, Joseph ;

Toy, Karen ;

Ha, Connie ;

Chen, Ying-Jiun ;

Stinson, Jeremy ;

Chaudhuri, Subhra ;

Zhang, Na ;

Wu, Thomas D. ;

Sugarbaker, David J. ;

de Sauvage, Frederic J. ;

Richards, William G. ;

Seshagiri, Somasekar .

NATURE GENETICS, 2016, 48 (04) :407-+

[3] Mesothelioma: Scientific clues for prevention, diagnosis, and therapy [J].

Carbone, Michele ;

Adusumilli, Prasad S. ;

Alexander, H. Richard, Jr. ;

Baas, Paul ;

Bardelli, Fabrizio ;

Bononi, Angela ;

Bueno, Raphael ;

Felley-Bosco, Emanuela ;

Galateau-Salle, Francoise ;

Jablons, David ;

Mansfield, Aaron S. ;

Minaai, Michael ;

de Perrot, Marc ;

Pesavento, Patricia ;

Rusch, Valerie ;

Severson, David T. ;

Taioli, Emanuela ;

Tsao, Anne ;

Woodard, Gavitt ;

Yang, Haining ;

Zauderer, Marjorie G. ;

Pass, Harvey, I .

CA-A CANCER JOURNAL FOR CLINICIANS, 2019, 69 (05) :402-429

[4] Immune checkpoint inhibitors in malignant pleural mesothelioma [J].

Ceresoli, Giovanni Luca ;

Mantovani, Alberto .

LANCET ONCOLOGY, 2017, 18 (05) :559-561

[5] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer [J].

Hellmann, M. D. ;

Paz-Ares, L. ;

Bernabe Caro, R. ;

Zurawski, B. ;

Kim, S. -W. ;

Carcereny Costa, E. ;

Park, K. ;

Alexandru, A. ;

Lupinacci, L. ;

de la Mora Jimenez, E. ;

Sakai, H. ;

Albert, I. ;

Vergnenegre, A. ;

Peters, S. ;

Syrigos, K. ;

Barlesi, F. ;

Reck, M. ;

Borghaei, H. ;

Brahmer, J. R. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Rabindran, S. K. ;

Kasinathan, R. S. ;

Nathan, F. E. ;

Ramalingam, S. S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) :2020-2031

[6] Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline [J].

Kindler, Hedy L. ;

Ismaila, Nofisat ;

Armato, Samuel G. ;

Bueno, Raphael ;

Hesdorffer, Mary ;

Jahan, Thierry ;

Jones, Clyde Michael ;

Miettinen, Markku ;

Pass, Harvey ;

Rimner, Andreas ;

Rusch, Valerie ;

Sterman, Daniel ;

Thomas, Anish ;

Hassan, Raffit .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (13) :1343-+

[7] Efficacy of nivolumab and ipilimumab in patients with malignant pleural mesothelioma is related to a subtype of effector memory cytotoxic T cells: Translational evidence from two clinical trials [J].

Mankor, Joanne M. ;

Disselhorst, Maria J. ;

Poncin, Myrthe ;

Baas, Paul ;

Aerts, Joachim G. J. V. ;

Vroman, Heleen .

EBIOMEDICINE, 2020, 62

[8] Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical-pathological features and intratumor heterogeneity over time [J].

Pasello, G. ;

Zago, G. ;

Lunardi, F. ;

Urso, L. ;

Kern, I ;

Vlacic, G. ;

Grosso, F. ;

Mencoboni, M. ;

Ceresoli, G. L. ;

Schiavon, M. ;

Pezzuto, F. ;

Pavan, A. ;

Vuljan, S. E. ;

Del Bianco, P. ;

Conte, P. ;

Rea, F. ;

Calabrese, F. .

ANNALS OF ONCOLOGY, 2018, 29 (05) :1258-1265

[9] A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial [J].

Popat, S. ;

Curioni-Fontecedro, A. ;

Dafni, U. ;

Shah, R. ;

O'Brien, M. ;

Pope, A. ;

Fisher, P. ;

Spicer, J. ;

Roy, A. ;

Gilligan, D. ;

Gautschi, O. ;

Nadal, E. ;

Janthur, W. D. ;

Castro, R. Lopez ;

Campelo, R. Garcia ;

Rusakiewicz, S. ;

Letovanec, I ;

Polydoropoulou, V ;

Roschitzki-Voser, H. ;

Ruepp, B. ;

Gasca-Ruchti, A. ;

Peters, S. ;

Stahel, R. A. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1734-1745

[10] Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial [J].

Scherpereel, Arnaud ;

Mazieres, Julien ;

Greillier, Laurent ;

Lantuejoul, Sylvie ;

Do, Pascal ;

Bylicki, Olivier ;

Monnet, Isabelle ;

Corre, Romain ;

Audigier-Valette, Clarisse ;

Locatelli-Sanchez, Myriam ;

Molinier, Olivier ;

Guisier, Florian ;

Urban, Thierry ;

Ligeza-Poisson, Catherine ;

Planchard, David ;

Amour, Elodie ;

Morin, Franck ;

Moro-Sibilot, Denis ;

Zalcman, Gerard .

LANCET ONCOLOGY, 2019, 20 (02) :239-253

← 1 2 →